CVS Health Corporation (CVS) earnings on May 6, 2026
More CVS Health Corporation earnings
Prior outlook: Optimistic Outcome: Accurate
CVS shares climbed strongly following its earnings announcement, even with some prior concerns. The positive results and outlook confirmed investor optimism, leading to a significant price increase.
CVS price around the earnings
86.86
Change: +7.6%
2026-05-06, 20:00 UTC
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- End of the measured window
- Market open
- Starting price
Prior thesis
Prior outlook: Optimistic Outcome: Accurate
- Thesis published
Strong fundamentals, positive outlook.
CVS has already benefited from a guidance increase, making the upcoming earnings report a less impactful event. Analysts remain very positive with strong conviction.
Context analyzed before publication
- Summary
- Strong fundamentals, positive outlook.
- Playbook
- The company's raised outlook and strong analyst support suggest continued positive performance. Further developments are a key factor.
- Trend
- Guidance raised, strong analyst conviction, solid momentum.
Analysts
Drivers
-
Analysts
Positive
A large number of analysts rate CVS as a 'strong buy', with price targets pointing to an optimistic scenario.
Evidence
- Analyst consensus
- Strong buy
- Consensus average (1-5)
- 1.44
- Analysts covering the stock
- 26
- Average price target
- 96.65
- Lowest price target
- 79
- Highest price target
- 140
- Upside to price target
- 12.8%
- Quarterly earnings growth
- 79%
- Revenue growth
- 8.4%
- Forward EPS
- 8.18
- Trailing EPS
- 1.39
- Analyst moves in the last 60 days
- 3
- Strong buy: 6
- Buy: 18
- Hold: 3
- Sell: 0
- Strong sell: 0
- Strong buy
- 6
- Buy
- 18
- Hold
- 3
- Sell
- 0
- Strong sell
- 0
- April 15, 2026 · Baird: Maintains rating (Outperform → Outperform)
- March 31, 2026 · Piper Sandler: Maintains rating (Overweight → Overweight)
- March 12, 2026 · Bernstein: Upgrades rating (Market Perform → Outperform)
News and sentiment
Drivers
-
News & sentiment
Positive
CVS Health has already increased its earnings and revenue forecasts for the year, signaling a strong business outlook.
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- Low
- Normalized volume
- 33%
News
Sources (5)
- CVS Health's Lower Medical Cost Ratio Lift Profit, Outlook — Benzinga
- CVS Health Raises FY2026 GAAP EPS Guidance from $5.94-$6.14 to $6.24-$6.44 vs $5.84 Est — Benzinga
- CVS Health Raises FY2026 Adj EPS Guidance from $7.00-$7.20 to $7.30-$7.50 vs $7.16 Est; FY2026 Revenue expected to be more than $405.000B vs $404.873B Est — Benzinga
- CVS Health Q1 Adj. EPS $2.57 Beats $2.20 Estimate, Sales $100.426B Beat $95.095B Estimate — Benzinga
- Baird Maintains Outperform on CVS Health, Raises Price Target to $94 — Benzinga
Technicals
Drivers
-
Technical
Positive
The stock is showing positive price momentum over the last month and is outperforming the broader market.
Evidence
- Average true range (ATR)
- 3.1%
- Distance to 52-week high
- -3.4%
- 14-day change (14d)
- +10.7%
- 30-day change
- +18.5%
- 30-day relative strength
- +6.5%
- Benchmark change
- +12.0%
- Nearest support
- 69.52
- Nearest resistance
- 88.58
- Volume accumulation ratio
- 1.07
Trends
Evidence
- Average earnings surprise
- -106.5%
- May 6, 2026: actual EPS 2.3 vs estimate 1.93 (surprise +19.5%)
- February 10, 2026: actual EPS 1.09 vs estimate 1 (surprise +9.4%)
- October 29, 2025: actual EPS -3.13 vs estimate 0.95 (surprise -430.1%)
- July 31, 2025: actual EPS 0.8 vs estimate 1.06 (surprise -24.6%)
Expected move
Drivers
-
Past earnings
Neutral
While past earnings surprises have been mixed, the recent positive guidance update is more significant for future expectations.
There is no implied-move data available for this event.
Reactions over its last 19 earnings
- Median move
- 3.5%
- 75th percentile move
- 5.7%
- 90th percentile move
- 12%
- Up / down moves
- 10 / 9
- Average up move
- +5.9%
- Average down move
- -3.9%
Monitoring and close
What CVS Health Corporation reported
There is no monitoring data available for this event.
Pre-market second reading after the results
There is no second reading available for this event.
How the stock reacted
- Outcome
- Accurate
- Consolidated
- +7.7%
- Max favorable move (MFE)
- 9.8%
- Max adverse move (MAE)
- 0%